GSK-LSD1 2HCl is an irreversible and selective LSD1 inhibitor (IC50 = 16 nM) with over 1000-fold selectivity over closely related FAD-dependent enzymes (e.g., LSD2, MAO-A, MAO-B); it induces gene expression changes in cancer cell lines (average EC50 < 5 nM) and inhibits cancer cell line proliferation (average EC50 < 5 nM).